Source comparison
BPC-157 vs Cortisone Injections: Full Comparison
Before reviewing this table, understand what it shows: direct head-to-head comparison of mechanism, clinical evidence, regulatory status, and practical outcomes. The 'Professional Assessment' column provides context that the raw data points alone don't convey.
This comparison does not assign a generated winner or score.
- Before reviewing this table, understand what it shows: direct head-to-head comparison of mechanism, clinical evidence, regulatory status, and practical outcomes. The 'Professional Assessment' column provides context that the raw data points alone don't convey.
- Primary Mechanism
- Glucocorticoid receptor binding → suppression of pro-inflammatory gene transcription (COX-2, IL-1, IL-6, TNF-alpha)
- VEGF and FGF upregulation → angiogenesis, fibroblast recruitment, collagen synthesis via eNOS-mediated NO pathway
- Cortisone stops the signal; BPC-157 rebuilds the structure. Fundamentally different therapeutic intent.
- Speed of Symptom Relief
- 24–48 hours. Pain reduction via prostaglandin inhibition
- 7–14 days. Tissue remodeling must occur before functional improvement
- If you need relief tomorrow, cortisone wins. If you need the tissue to actually heal, BPC-157 has the mechanistic edge.
- Effect on Collagen Synthesis
- Inhibits fibroblast activity; reduces type I collagen production by up to 50% (in vitro data)
- Increases collagen type I density by 40% at injury site (rodent Achilles model, 14-day endpoint)
- Cortisone weakens tissue while reducing pain. BPC-157 strengthens tissue while pain resolves more slowly.
- FDA Approval Status
- FDA-approved for inflammatory and autoimmune conditions; decades of clinical use
- Not FDA-approved for human use; classified as research peptide only
- Cortisone is legally prescribed. BPC-157 is sourced off-label or through research channels. Legality is context-dependent.
- Re-Injury Risk Post-Treatment
- 63% higher rotator cuff tear rate vs no injection (AJSM 2019); 3.7% Achilles rupture rate within 6 months (cohort n=8,700)
- Rodent studies show 28% higher load-to-failure threshold vs saline controls; no human rupture data available
- Cortisone objectively increases structural failure risk. BPC-157 data is preclinical but mechanistically supports reduced re-injury.
- Documented Side Effects
- Localized fat atrophy, hypopigmentation, post-injection flare (10%), tendon rupture, HPA axis suppression with repeat dosing
- Minimal adverse effects in animal models; primary risk is contamination/misdosing from unregulated suppliers
- Cortisone's risks are known and dose-dependent. BPC-157's risks are unknown in humans beyond supplier quality issues.